Navigation Links
Techne Corporation Announces That John L. Higgins has Accepted a Seat on Techne's Board
Date:5/19/2009

MINNEAPOLIS, May 19 /PRNewswire-FirstCall/ -- Techne Corporation (Nasdaq: TECH) today announced that Mr. John L. Higgins has accepted a position on Techne's Board of Directors and will also serve as a member of Techne's Audit, Compensation and Nominations and Governance Committees. Mr. Higgins' initial term will begin immediately and run through October 29, 2009. Techne's shareholders reelect Directors on an annual basis.

Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals Incorporated since January 2007 and has been a member of Ligand's Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006.

Mr. Higgins was previously a member of the executive management team at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Currently, he is a Director of BioCryst and serves as Chairperson of its Audit Committee. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins also serves as Chairman of CoMentis, Inc, a biopharmaceutical company, and has served as a director of numerous public and private companies. He graduated Magna Cum Laude with an A.B. from Colgate University.

Mr. Thomas E. Oland, Techne's Chairman and CEO, said, "I am extremely pleased with Mr. Higgins' decision to accept a position on Techne's Board. His combination of biopharmaceutical business experience and background as a chief financial officer and investment banker, combined with his current responsibilities as a CEO, are all essential qualifications that will benefit Techne. We are very fortunate to have a person of his caliber on our Board. I am very confident that he will make a significant contribution to our future success."

Techne Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of biological products. R&D Systems has two subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China. BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. R&D China and R&D Europe distribute biotechnology products.


'/>"/>
SOURCE Techne Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009
2. Techne Corporation Declares Dividend and Announces an Increase in Its Share Repurchase Program
3. Techne Corporation Declares Dividend
4. Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009
5. Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008
6. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
7. Techne Corporation Announces Share Repurchase Authorization
8. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
9. Odyssey Thera Announces Collaboration With Mitsubishi Tanabe Pharma Corporation, and Issuance of Core Patent in Japan
10. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
11. Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... DUBLIN , Feb 17, 2017 Research ... Global Strategic Business Report" report to their offering. ... The report provides separate ... Europe , and Rest of World. Annual estimates and ... six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... MILPITAS, Calif. , Feb. 17, 2017 /PRNewswire/ ... posters detailing data on its oral peptide drug ... Congress of the European Crohn,s and Colitis ... in Barcelona, Spain from ... The posters detail preclinical data on Protagonist drug ...
(Date:2/16/2017)... 16, 2017  MDNA Life Sciences Inc. (MDNA), ... liquid biopsy tests based on the mitochondrial genome, ... license agreement with its first international commercial partner, ... test for prostate cancer, the Prostate Mitomic Test ... This is the first overseas appointment for MDNA ...
(Date:2/16/2017)... BEACH, Florida , February 16, 2017 /PRNewswire/ ... improving with the infusion of innovative telemedicine application, ... monitoring services that are experiencing a boom worldwide. ... with the advancement of technologies, services and new ... Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. ...
Breaking Biology Technology:
(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
(Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
Breaking Biology News(10 mins):